Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
Sponsor: Kafrelsheikh University
Summary
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. Silymarin has clinical evidence supports its use as an adjunctive hepatoprotective agent due to antioxidant, anti-inflammatory, and antifibrotic effects.
Official title: A Randomized Controlled Evaluation of Vitamin E Versus Silymarin on Liver Through Modulation of mRNA Profiles, NLRP3 Inflammasome Signaling, and Oxidative Stress in Non Diabetic MASLD Patients
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-10-16
Completion Date
2027-09-01
Last Updated
2026-10-07
Healthy Volunteers
No
Interventions
Vitamin E 800 IU/d
Participants in Vitamin E Group will receive oral vitamin E at dose of 800 IU/d for a total duration of 24 weeks
Silymarin 420 mg
Participants in Silymarin Group will receive oral silymarin at dose of 420 mg/d for a total duration of 24 weeks
Placebo
participants in Placebo Group will receive an oral placebo capsule, identical in appearance to the active interventions once daily for 24 weeks
Locations (1)
Faculty of Medicine
Tanta, Egypt